People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical trial results from Lilly.

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

I f you're a FuturHealth member, you'll now have a free membership to Apple Fitness Plus as part of your program. It's Apple Fitness Plus’s first direct integration with a personalized GLP-1 weight ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Overview As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 market and ramping up efforts to address the perceived risks associated ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.